Cafeity Get the app

Living with it

Contraception, pregnancy and breastfeeding

Three things surprise people here: that some GLP-1 medicines can make birth control pills less reliable for a while, that semaglutide needs to be stopped months before a planned pregnancy, and that the rules for breastfeeding differ between the injection and the tablet. All three are in the labels.

By the Cafeity teamUpdated 3 min read

The short answer

Some GLP-1 labels say oral contraceptives may work less well for a time: tirzepatide's advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase, and orforglipron's for 30 days.12 Semaglutide's label advises stopping at least 2 months before a planned pregnancy because of its long half-life.3 The weight-management labels say to stop treatment when a pregnancy is recognised. Breastfeeding is not recommended on semaglutide tablets or orforglipron; for the injections, the labels ask you to weigh the benefits with your prescriber.32

Birth control pills

These medicines slow stomach emptying, which can change how other tablets are absorbed. For oral contraceptives, two labels give specific instructions:12

Label instructions on oral hormonal contraceptives. Non-oral methods (implants, injections, coils, patches, rings) are not affected by this interaction.
MedicineWhat the label advises
TirzepatideSwitch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
OrforglipronSwitch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase. The label also advises effective contraception throughout treatment for women who could become pregnant.

Talk to your prescriber about the method that suits you before starting.

Planning a pregnancy

The semaglutide label advises stopping at least 2 months before a planned pregnancy, specifically because of its long half-life.3 The tirzepatide label asks patients to tell their healthcare provider if they intend to become pregnant.1 Animal studies with these medicines have shown risks to the fetus, and the human data are insufficient to establish safety.312 Plan the timing with your prescriber.

If you become pregnant

The weight-management labels say to stop treatment when a pregnancy is recognised, and note that weight loss is not recommended during pregnancy.13 Tell your prescriber straight away. Manufacturers run pregnancy exposure registries that collect outcomes; your prescriber can tell you how to take part.

Breastfeeding

What each label says about breastfeeding.
MedicineLabel position
Semaglutide tabletsBreastfeeding is not recommended, because of an absorption enhancer in the tablet that passes into milk.
Semaglutide injectionNo data; weigh the benefits of breastfeeding against the need for the medicine with your prescriber.
Tirzepatide injectionIn a single-dose study, levels in breast milk were undetectable or low; weigh benefits and risks with your prescriber.
Orforglipron tabletsNot recommended for nursing women.
Liraglutide injectionNo human data; weigh benefits and risks with your prescriber.

Sources: prescribing information.3124

Common questions

Do GLP-1 medicines affect birth control pills?
Some do: the tirzepatide label advises a non-oral or added barrier method for 4 weeks after starting and after each increase, and the orforglipron label for 30 days.12
How long before trying to conceive should I stop semaglutide?
The label advises at least 2 months before a planned pregnancy.3
Can I breastfeed on a GLP-1?
It depends on the medicine: not recommended on semaglutide tablets or orforglipron; for the injections, the labels ask you to weigh it up with your prescriber.321

Sources

  1. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  2. Orforglipron tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 13 August 2026
  3. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026
  4. Liraglutide 3 mg injection for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 15 June 2026

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.